For research use only. Not for therapeutic Use.
IKK-3 inhibitor (Cat.No:I005172) is a small molecule compound that selectively inhibits the activity of the IKK-ε kinase, also known as IKK-3. This enzyme plays a crucial role in the regulation of immune responses and inflammation. By blocking IKK-3, this inhibitor has potential therapeutic applications in inflammatory diseases and cancer treatment.
| Catalog Number | I005172 |
| CAS Number | 862812-98-4 |
| Synonyms | 5-(5,6-dimethoxy-1H-benzo[d]imidazol-1-yl)-3-((2-(methylsulfonyl)benzyl)oxy)thiophene-2-carbonitrile |
| Molecular Formula | C22H19N3O5S2 |
| Purity | ≥95% |
| Target | IKK |
| Solubility | 10 mM in DMSO |
| Storage | Store at -20°C |
| IC50 | 40 nM |
| InChI | InChI=1S/C22H19N3O5S2/c1-28-17-8-15-16(9-18(17)29-2)25(13-24-15)22-10-19(20(11-23)31-22)30-12-14-6-4-5-7-21(14)32(3,26)27/h4-10,13H,12H2,1-3H3 |
| InChIKey | LDTAHRLHGHFHKP-UHFFFAOYSA-N |
| SMILES | CS(C1=C(COC2=C(C#N)SC(N3C=NC4=CC(OC)=C(OC)C=C43)=C2)C=CC=C1)(=O)=O |
| Reference | </br>1:A novel EGFR-TKI inhibitor (cAMP-H3BO3 complex) combined with thermal therapy is a promising strategy to improve lung cancer treatment outcomes. Tong Y, Huang C, Zhang J.Oncotarget. 2017 May 5. doi: 10.18632/oncotarget.17628. [Epub ahead of print] PMID: 28525890 </br>2:Role of Cost-Sharing Subsidies on the Initiation of and Adherence to Tyrosine Kinase Inhibitor Therapy by Medicare Beneficiaries With Chronic Myeloid Leukemia. Ritchie EK, Guerin A, Wolff J, Joseph G.J Clin Oncol. 2017 May 20;35(15):1744-1745. doi: 10.1200/JCO.2016.72.0011. Epub 2017 Feb 13. No abstract available. PMID: 28524780 </br>3:Retinoid BMS411 (4-{[(5,5-dimethyl-8-phenyl-5,6-dihydronaphthalen-2-yl) carbonyl] amino} benzoic acid), a potential inhibitor of NS5A protein of hepatitis C virus, a candidate for combined therapy of hepatitis C infection. Ibrahim S, Asad MJ, Mahmood RT, Wattoo FH, Akhter S, Shahwar D.Acta Virol. 2017;61(2):204-211. doi: 10.4149/av_2017_02_11. PMID: 28523927 </br>4:Identification of a novel putative inhibitor of the Plasmodium falciparum purine nucleoside phosphorylase: exploring the purine salvage pathway to design new antimalarial drugs. Kagami LP, das Neves GM, Rodrigues RP, da Silva VB, Eifler-Lima VL, Kawano DF.Mol Divers. 2017 May 18. doi: 10.1007/s11030-017-9745-8. [Epub ahead of print] PMID: 28523625 </br>5:The respiratory chain inhibitor rotenone affects peroxisomal dynamics via its microtubule-destabilising activity. Passmore JB, Pinho S, Gomez-Lazaro M, Schrader M.Histochem Cell Biol. 2017 May 18. doi: 10.1007/s00418-017-1577-1. [Epub ahead of print] PMID: 28523458 </br>6:Three-dimensional organ scanning reveals brain edema reduction in a rat model of stroke treated with an aquaporin 4 inhibitor. Popescu ES, Pirici I, Ciurea RN, Bălşeanu TA, Cătălin B, Mărgăritescu C, Mogoantă L, Hostiuc S, Pirici D.Rom J Morphol Embryol. 2017;58(1):59-66. PMID: 28523299 </br>7:Roles of roflumilast, a selective phosphodiesterase 4 inhibitor, in airway diseases. Kawamatawong T.J Thorac Dis. 2017 Apr;9(4):1144-1154. doi: 10.21037/jtd.2017.03.116. Review. PMID: 28523172 </br>8:Human Serum Albumin-Delivered [Au(PEt<sub>3</sub>)]<sup>+</sup> Is a Potent Inhibitor of T Cell Proliferation. Dean TC, Yang M, Liu M, Grayson JM, DeMartino AW, Day CS, Lee J, Furdui CM, Bierbach U.ACS Med Chem Lett. 2017 Apr 25;8(5):572-576. doi: 10.1021/acsmedchemlett.7b00142. eCollection 2017 May 11. PMID: 28523113 </br>9:INCB24360 (Epacadostat), a Highly Potent and Selective Indoleamine-2,3-dioxygenase 1 (IDO1) Inhibitor for Immuno-oncology. Yue EW, Sparks R, Polam P, Modi D, Douty B, Wayland B, Glass B, Takvorian A, Glenn J, Zhu W, Bower M, Liu X, Leffet L, Wang Q, Bowman KJ, Hansbury MJ, Wei M, Li Y, Wynn R, Burn TC, Koblish HK, Fridman JS, Emm T, Scherle PA, Metcalf B, Combs AP.ACS Med Chem Lett. 2017 Mar 6;8(5):486-491. doi: 10.1021/acsmedchemlett.6b00391. eCollection 2017 May 11. PMID: 28523098 </br>10:Sensitization of EGFR wild-type non-small cell lung cancer cells to EGFR-tyrosine kinase inhibitor erlotinib. Raimbourg J, Joalland MP, Cabart M, de Plater L, Bouquet F, Savina A, Decaudin D, Bennouna J, Vallette FM, Lalier L.Mol Cancer Ther. 2017 May 18. pii: molcanther.0075.2017. doi: 10.1158/1535-7163.MCT-17-0075. [Epub ahead of print] PMID: 28522592 |
